{"id":"W3164179066","doi":"10.1136/rmdopen-2021-001595","title":"Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure","year":2021,"lang":"en","type":"article","venue":"RMD Open","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Genentech; Bausch Health; Celltrion; Astellas Pharma; Sanofi; Kyowa Hakko Kirin; Coherus Biosciences; Sun Pharma; Dermira; F. Hoffmann-La Roche; Ironwood Pharmaceuticals, Incorporated; Regeneron Pharmaceuticals; Baxalta; Boston Pharmaceuticals; LEO Pharma; Gilead Sciences; GlaxoSmithKline; Allergan; AstraZeneca; Seres Therapeutics; Amgen; Meiji Seika Pharma; Pfizer; Celgene; Galderma; Celltrion Healthcare; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Tofacitinib; Medicine; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Psoriasis; Internal medicine; Adverse effect; Clinical trial; Arthritis; Incidence (geometry); Dermatology; Disease","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00231521,0.0002057165,0.002022069,0.0001501022,0.00003726792,0.00002198172,0.0002027484,0.0001470424,0.001209477],"category_scores_gemma":[0.003449873,0.0001931723,0.0002119937,0.0003384161,0.0003918836,0.0002829162,0.0002547315,0.000301428,0.000005623385],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002887255,"about_ca_system_score_gemma":0.0006259464,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003893665,"about_ca_topic_score_gemma":0.004569492,"domain_scores_codex":[0.9951002,0.001402396,0.002293716,0.0004204622,0.0004606938,0.0003225536],"domain_scores_gemma":[0.9972879,0.0008921802,0.000755341,0.0004088764,0.0004235602,0.0002321998],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01138616,0.001656652,0.1284164,0.0002616839,0.0007769088,0.0004537853,0.004425823,0.000002690083,0.0004868825,0.002653245,0.0007420586,0.8487378],"study_design_scores_gemma":[0.1223115,0.01188357,0.7681891,0.02866913,0.0000391681,0.0005282626,0.01846672,0.00002838886,0.02998244,0.003717238,0.01541667,0.0007677979],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907032,0.006109555,0.00001001625,0.0001507622,0.0002249547,0.001460797,0.0006045627,0.000006683276,0.000729498],"genre_scores_gemma":[0.8849588,0.1137052,0.001002327,0.00003583577,0.00008344416,0.00005928659,0.00009948837,0.00002498357,0.00003064431],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8479699,"threshold_uncertainty_score":0.9997035,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06746329276828503,"score_gpt":0.3602680577919297,"score_spread":0.2928047650236446,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}